Show the full website


Vaccibody CEO after billion-kroner deal: "In five years, we'll be a global biotech player with a broad pipeline"

Vaccibody CEO Michael Engsig is "extremely proud" the company has landed a partnership deal worth DKK 4.5bn with Genentech. This provides the pharmaceutical with an opportunity to expand its pipeline and delve into other disease areas.

Foto: Vaccibody / PR

Thursday morning saw the starting signal of a new era for the Oslo-based biotech company Vaccibody.

Vaccibody's Danish CEO Michael Engsig sheds light on this, as the firm has entered into a partnership with the biotech giant Genentech on Vaccibody's tailored cancer vaccine VB10.NEO, which posts around DKK 4.5bn (USD 710m) in the company.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Receive newsletter from MedWatch today

NB: Subscribing to the newsletter is free.

More from MedWatch


See all jobs